REG - MyHealthChecked PLC - Approval for UK Government Test to Release scheme

MyhealthcheckedAnnouncement

29/12/2020 07:01

RNS Number : 8923J
  
MyHealthChecked PLC
  
29 December 2020
  
 

MyHealthChecked Plc
("MyHealthChecked" or the "Company") 
 
Approved provider for UK Government Test to Release scheme
 
MyHealthChecked Plc (AIM: MHC), the personalised healthcare company, announces that Concepta Diagnostics' MyHealthChecked™ COVID-19 testing service has been added to the UK Government's approved COVID-19 private testing providers list* for General Testing, and the Test to Release for International Travel scheme introduced on 15 December 2020 ("Test to Release").
 
The Test to Release scheme is a UK Government backed programme, designed to reduce quarantine periods for travellers arriving in the UK. Through the Test to Release scheme, passengers have the opportunity to pay for a COVID-19 test through the list of approved private providers, to find out if they are able to reduce the self-isolation period after international travel. 
 
MyHealthChecked™ COVID-19 testing service has the full COVID-19 testing service offering required to meet the Department of Health & Social Care's 15 minimum standards**. MyHealthChecked's Test to Release scheme will go live in January 2021.
 
Commenting on the approval, Penny McCormick, CEO of MyHealthChecked Plc, said: 
"Our COVID-19 testing service launched on 2 December and has gathered momentum through the month. As we are already providing Fit to Fly documentation, our inclusion on the Government's official list of Test to Release providers will further enhance the service that we can provide to travellers departing the UK, and flying into the country. Our priority is to provide an excellent service to customers, which includes a robust web App and user interface that is compliant and provides a positive user experience. We have been confident that our process would meet the Government's requirements, and we will be rolling out the enhanced system and service from January."
 
"Alongside this further COVID-19 related development, our team continues with its initial development and rollout plans for the new portfolio of home-use genomic tests, and we will be providing an update on our Q1 launch plans in the coming weeks."
 
*The list of approved private providers can be found here: https://bit.ly/2J7unFk
**More information on the minimum standards set out by the Department of Health & Social Care can be found here: https://bit.ly/3pfSDnZ 
 



MyHealthChecked Plc


www.myhealthcheckedplc.com




Penny McCormick, Chief Executive Officer


via Walbrook PR




Maddy Kennedy, Chief Financial Officer


















SPARK Advisory Partners Limited (NOMAD)


Tel: +44 (0)20 3368 3550




Neil Baldwin 


















Novum Securities (Joint Broker)


Tel: +44 (0)20 7399 9400




Colin Rowbury


















Oberon Capital Ltd (Joint Broker)


Tel: +44 (0)203 179 5344




Mike Seabrook


mikeseabrook@oberoninvestments.com














Walbrook PR Ltd (Media & Investor Relations)


Tel: +44 (0)20 7933 8780 or myhealthchecked@walbrookpr.com




Paul McManus


Mob: +44(0)7980 541 893 



 
About MyHealthChecked PLC (www.myhealthcheckedplc.com) 
MyHealthChecked PLC, based in Cardiff, is an AIM-quoted pioneering UK healthcare company with two diverse, customer-facing at-home testing brands in its portfolio:
 
MyHealthChecked is the umbrella brand of a range of at-home DNA and RNA tests, now in development following the recent acquisition of The Genome Store. The tests will be made available on line, and would be viable for over the counter purchase. 
 
The MyHealthChecked portfolio has been identified as part of a change in mindset as customers become more familiar with the concept of accessible healthcare in the growing at home testing kit market with a focus on accessibility at the right price, led by UK-based experts. 
 
Mylo targets the personalized mobile health market, with a primary focus on hormone testing and increasing a woman's chances of naturally getting pregnant, and providing insight to unexplained infertility. The myLotus range of IVDs are CE-marked and are expected to be beneficial to users who have been unable to conceive after 6 months of trying. This highly motivated target group of women won't typically be offered medical intervention until after 12 months of unsuccessfully trying to conceive, with IVF not usually offered until after two years of trying to conceive. Research indicates couples start to take positive action ahead of this time typically with little medical support to help them do so.
 
The myLotus range of IVDs are currently the UK's only consumer product which allows both quantitative and qualitative home (self-test) test measurement of a woman's personal luteinizing hormone (LH) during ovulation and human chorionic gonadotropin ("hCG") hormone level during pregnancy.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
REAPPGQCPUPUGPR